<DOC>
	<DOCNO>NCT00851643</DOCNO>
	<brief_summary>This study examine safety tolerability octavalent Human Papillomavirus ( HPV ) L1 Virus-Like Particle ( VLP ) vaccine formulate amorphous aluminum hydroxysulfate ( AAHS ) ISCOMATRIXâ„¢ ( IMX ) . Reviews safety tolerability use select dose ( ) IMX study octavalent HPV L1 VLP vaccine .</brief_summary>
	<brief_title>Broad Spectrum HPV Vaccine Dose Escalation Study ( V502-002 )</brief_title>
	<detailed_description>The study perform 2 staggered phase , Phase A Phase B . In Phase A , participant randomize qHPV , Octavalent HPV 15 mcg IMX/AAHS , Octavalent HPV 30 mcg IMX/AAHS . After safety Phase A reviewed , Phase B initiate . In Phase B , participant randomize qHPV , Octavalent HPV 60 mcg IMX/AAHS Octavalent HPV 120 mcg IMX/AAHS .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant good physical health Participant lifetime history 0 4 sexual partner Females 18to24 year Participant history abnormal Pap test Participant history positive test HPV Participant history recent ongoing alcohol drug abuse Participant immunocompromised autoimmune condition Participant receive immunosuppressive therapy within year screen Participant previously receive HPV vaccine Participant pregnant Participant history external genital/vaginal wart Participant currently enrol clinical trial Participant history severe allergic reaction require medical attention</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>